Effectiveness of Chemoterapy in Advanced PanNETs with ki67<55%: Monocentric Experience

#1706

Introduction: Pancreatic Neuroendocrine Tumors (panNETs) are neoplasms with heterogeneous clinical behaviour. There is no standard treatment.

Aim(s): The aim of this study is an evaluation of different chemotherapy regimen in first or subsequent line of treatment in advanced panNET with ki67<55 (“G3 low”).

Materials and methods: We retrospectively reviewed data from 45 patients (P) with locally advanced or metastatic pNET treated with chemoterapy during 2011-2016. Mixed histology and ki67> 55% were excluded. 60% P received two drugs (2C) combination (STZ or platinum or TMZ based) and 40% tree drugs (3C) (mFOLFIRINOX or DTIC+CDDP+5FU). We evalueted separately the two groups. According to the WHO classification there were respectively 3,7% and 5,6% G1; 59,3 % and 27,8% G2; 37% and 66,7% “G3 low”. 89,3% of P in the 2C group (48% liver only) and 83,3% in 3C (33,3% liver only) had metastatic desease. Morphological response was assessed according to RECIST1.1 criteria.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Antista M, Cingarlini S, Grego E, Ortolani S, Scarpa A,

Keywords: chemotherapy, neuroendocrine, pan NETs, ki67<55%,

To read the full abstract, please log into your ENETS Member account.